Cookie Control Our global sites Open Search About us Our science Our products Investors Sustainability Careers Get in touch Financial highlights Allergy Therapeutics PLC Financial highlights Overview At a glance Financial highlights Investment case Regulatory news Email alert Results, reports and presentations Financial Calendar Share tools Shareholder services AIM Rule 26 Corporate governance Investor and Advisor Contacts 2021: Our year in numbers 8% revenue growth in actual terms and 6% at constant rate* to £84.3m (2020: £78.2m) 19% increase in pre-R&D operating profit to £16.9m (2020: £14.2m) as a result of sales growth and lower overhead cost growth Strong cash balance of £40.3m at 30 June 2021 (2020: £37.0m) Net profit of £2.9m for the year (2020: Net profit of £7.1m including cash settlement of £3.2m) * Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year on year comparison excluding the effects of foreign exchange movements. Related links Annual Report 2020 Click here to read this years Annual Report. Annual Report 2020 Investors Allergy Therapeutics Investor Relations Centre. Overview Get in touch Contact us. Get in touch Click for top of the page Linkedin icon Quick links Head office General inquiries Terms and Conditions Privacy Statement Cookies Adverse Event Reporting Modern Slavery and Human Trafficking Statement Gender Pay Gap QCA Code Compliance statement Contact us Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom Tel +44 (0)1903 844 700 © Allergy Therapeutics 2021. By Emperor